QuidelOrtho (QDEL) Competitors

QuidelOrtho logo
$12.21 +0.27 (+2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$12.22 +0.00 (+0.04%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

Should you buy QuidelOrtho stock or one of its competitors? MarketBeat compares QuidelOrtho with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with QuidelOrtho include ICU Medical (ICUI), Haemonetics (HAE), DENTSPLY SIRONA (XRAY), Neogen (NEOG), and STAAR Surgical (STAA). These companies are all part of the "health care supplies" industry.

How does QuidelOrtho compare to ICU Medical?

ICU Medical (NASDAQ:ICUI) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, QuidelOrtho had 3 more articles in the media than ICU Medical. MarketBeat recorded 3 mentions for QuidelOrtho and 0 mentions for ICU Medical. ICU Medical's average media sentiment score of 0.73 beat QuidelOrtho's score of 0.70 indicating that ICU Medical is being referred to more favorably in the media.

Company Overall Sentiment
ICU Medical Positive
QuidelOrtho Positive

ICU Medical currently has a consensus target price of $168.40, indicating a potential upside of 17.80%. QuidelOrtho has a consensus target price of $14.88, indicating a potential upside of 21.83%. Given QuidelOrtho's higher possible upside, analysts plainly believe QuidelOrtho is more favorable than ICU Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ICU Medical
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
QuidelOrtho
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

96.1% of ICU Medical shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 2.1% of ICU Medical shares are owned by insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ICU Medical has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICU Medical$2.23B1.60$730K$1.8577.27
QuidelOrtho$2.73B0.30-$1.13B-$17.82N/A

ICU Medical has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

ICU Medical has a net margin of 2.15% compared to QuidelOrtho's net margin of -45.57%. ICU Medical's return on equity of 7.50% beat QuidelOrtho's return on equity.

Company Net Margins Return on Equity Return on Assets
ICU Medical2.15% 7.50% 3.91%
QuidelOrtho -45.57%4.25%1.56%

Summary

ICU Medical beats QuidelOrtho on 12 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to Haemonetics?

Haemonetics (NYSE:HAE) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Haemonetics presently has a consensus price target of $78.33, indicating a potential upside of 7.53%. QuidelOrtho has a consensus price target of $14.88, indicating a potential upside of 21.83%. Given QuidelOrtho's higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Haemonetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
QuidelOrtho
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Haemonetics has a net margin of 7.29% compared to QuidelOrtho's net margin of -45.57%. Haemonetics' return on equity of 27.30% beat QuidelOrtho's return on equity.

Company Net Margins Return on Equity Return on Assets
Haemonetics7.29% 27.30% 9.59%
QuidelOrtho -45.57%4.25%1.56%

Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

In the previous week, QuidelOrtho had 2 more articles in the media than Haemonetics. MarketBeat recorded 3 mentions for QuidelOrtho and 1 mentions for Haemonetics. QuidelOrtho's average media sentiment score of 0.70 beat Haemonetics' score of 0.32 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Haemonetics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
QuidelOrtho
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Haemonetics has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$1.33B2.48$97.31M$2.0236.06
QuidelOrtho$2.73B0.30-$1.13B-$17.82N/A

Summary

Haemonetics beats QuidelOrtho on 12 of the 17 factors compared between the two stocks.

How does QuidelOrtho compare to DENTSPLY SIRONA?

QuidelOrtho (NASDAQ:QDEL) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DENTSPLY SIRONA has a net margin of -17.06% compared to QuidelOrtho's net margin of -45.57%. DENTSPLY SIRONA's return on equity of 18.83% beat QuidelOrtho's return on equity.

Company Net Margins Return on Equity Return on Assets
QuidelOrtho-45.57% 4.25% 1.56%
DENTSPLY SIRONA -17.06%18.83%5.13%

QuidelOrtho has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, DENTSPLY SIRONA had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 5 mentions for DENTSPLY SIRONA and 3 mentions for QuidelOrtho. DENTSPLY SIRONA's average media sentiment score of 1.23 beat QuidelOrtho's score of 0.70 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
QuidelOrtho
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DENTSPLY SIRONA
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DENTSPLY SIRONA has higher revenue and earnings than QuidelOrtho. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QuidelOrtho$2.73B0.30-$1.13B-$17.82N/A
DENTSPLY SIRONA$3.68B0.57-$598M-$3.15N/A

QuidelOrtho presently has a consensus target price of $14.88, suggesting a potential upside of 21.83%. DENTSPLY SIRONA has a consensus target price of $13.55, suggesting a potential upside of 28.76%. Given DENTSPLY SIRONA's stronger consensus rating and higher probable upside, analysts clearly believe DENTSPLY SIRONA is more favorable than QuidelOrtho.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QuidelOrtho
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
DENTSPLY SIRONA
3 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

DENTSPLY SIRONA beats QuidelOrtho on 13 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to Neogen?

Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

QuidelOrtho has a net margin of -45.57% compared to Neogen's net margin of -69.93%. QuidelOrtho's return on equity of 4.25% beat Neogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Neogen-69.93% 2.35% 1.46%
QuidelOrtho -45.57%4.25%1.56%

Neogen presently has a consensus price target of $10.67, suggesting a potential upside of 16.19%. QuidelOrtho has a consensus price target of $14.88, suggesting a potential upside of 21.83%. Given QuidelOrtho's higher possible upside, analysts plainly believe QuidelOrtho is more favorable than Neogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neogen
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
QuidelOrtho
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, QuidelOrtho had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for QuidelOrtho and 2 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.70 beat Neogen's score of 0.69 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neogen
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
QuidelOrtho
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neogen has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

96.7% of Neogen shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 0.6% of Neogen shares are held by company insiders. Comparatively, 1.1% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neogen has higher earnings, but lower revenue than QuidelOrtho. Neogen is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$894.66M2.23-$1.09B-$2.80N/A
QuidelOrtho$2.73B0.30-$1.13B-$17.82N/A

Summary

QuidelOrtho beats Neogen on 10 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by insiders. Comparatively, 1.1% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

STAAR Surgical currently has a consensus target price of $27.81, suggesting a potential downside of 3.83%. QuidelOrtho has a consensus target price of $14.88, suggesting a potential upside of 21.83%. Given QuidelOrtho's higher probable upside, analysts plainly believe QuidelOrtho is more favorable than STAAR Surgical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STAAR Surgical
2 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.09
QuidelOrtho
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

STAAR Surgical has higher earnings, but lower revenue than QuidelOrtho. STAAR Surgical is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$239.44M6.01-$80.45M-$0.43N/A
QuidelOrtho$2.73B0.30-$1.13B-$17.82N/A

STAAR Surgical has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

STAAR Surgical has a net margin of -7.24% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat STAAR Surgical's return on equity.

Company Net Margins Return on Equity Return on Assets
STAAR Surgical-7.24% 3.31% 2.55%
QuidelOrtho -45.57%4.25%1.56%

In the previous week, QuidelOrtho had 2 more articles in the media than STAAR Surgical. MarketBeat recorded 3 mentions for QuidelOrtho and 1 mentions for STAAR Surgical. QuidelOrtho's average media sentiment score of 0.70 beat STAAR Surgical's score of 0.40 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STAAR Surgical
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
QuidelOrtho
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

STAAR Surgical beats QuidelOrtho on 9 of the 16 factors compared between the two stocks.

Get QuidelOrtho News Delivered to You Automatically

Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QDEL vs. The Competition

MetricQuidelOrthoMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$813.86M$8.35B$6.74B$12.32B
Dividend YieldN/A2.57%2.68%5.88%
P/E Ratio-0.6915.2125.3923.96
Price / Sales0.307.01530.17107.90
Price / Cash0.6316.9345.2953.76
Price / Book0.433.2910.766.41
Net Income-$1.13B$226.25M$3.56B$337.14M
7 Day Performance-7.01%-0.96%1.37%-0.48%
1 Month Performance2.95%-2.77%0.81%0.49%
1 Year Performance-57.41%0.16%30.53%28.16%

QuidelOrtho Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QDEL
QuidelOrtho
3.1185 of 5 stars
$12.21
+2.3%
$14.88
+21.8%
-56.8%$813.86M$2.73BN/A6,500
ICUI
ICU Medical
3.425 of 5 stars
$136.14
-3.0%
$168.40
+23.7%
+6.1%$3.51B$2.23B73.5913,000
HAE
Haemonetics
2.3618 of 5 stars
$72.56
-2.2%
$78.33
+8.0%
+1.1%$3.37B$1.33B35.923,009
XRAY
DENTSPLY SIRONA
4.8677 of 5 stars
$10.15
-1.7%
$13.55
+33.5%
-34.1%$2.07B$3.68BN/A14,000
NEOG
Neogen
1.6372 of 5 stars
$8.92
-4.2%
$10.67
+19.6%
+85.1%$2.03B$894.66MN/A2,110

Related Companies and Tools


This page (NASDAQ:QDEL) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners